ALS Limited announced robust FY2022 results

ALS Limited (ASX: ALQ) has released its FY2022 for the period ended 31 March 2922.

• Revenue of the Company increased by 23.9% to AU$2,182.3 million, driven by due to strong performance from Life Sciences and Commodities.
• Statutory net profit after tax was up AU$20.9million to AU$190.5 million following the continued strong performance in the 2nd half, partially offset by non-operational one-off costs.
• Underlying NPAT improved 42.1% to AU$264.2 million.
• Underlying EPS increased 42.1% to 54.7 cents per share and statutory EPS by 12.2% to 39.5 cents per share.
• ALQ declared a final dividend of AU17.0 cents per share (30% franked). Thus, total dividend for FY2022 was 32.8 cps, up 42% compared to the previous corresponding period.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au